MGC Pharmaceuticals Ltd.
Issue of New Shares Completed in 2021
10 February 2022
ASX, LSE: MXC
MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') wishes to make a formal notification regarding share issues that have occurred following the Company's IPO listing on the London Stock Exchange on 9 February 2021, and prior to the UK Placing in December 2021.
As the Company is dual listed, requisite compliance documentation for the quotation of these new shares lodged with on the Australian Securities Exchange (ASX), being Appendix 2As "Application for Quotation Securities", were also released on RNS.
MGC is now applying for admission of these shares to the FCA's Official List, and for trading on the Main Market of the LSE, as such, MGC Pharma wishes to advise that it issued 194,010,702 new shares between 4 March 2021 and 24 November 2021 for which it is applying for admission to trading on the LSE from 8:00am (GMT) on 16 February 2022.
As noted above, these shares are not in addition to previously announced share issues during the period stated above, and this announcement is being made for UK Regulatory listing and disclosure requirements only.
--Ends--
Authorised for release by the Chairman, for further information please contact:
| MGC Pharmaceuticals Ltd Roby Zomer CEO & Managing Director +61 8 6382 3390 | MGC Pharmaceuticals Ltd David Lim Company Secretary +61 8 6382 3390 |
| UK Broker - Turner Pope Andy Thacker +44 203 657 0050 | UK PR Advisors - Tavistock Charles Vivian / Tim Pearson +44 207 920 3150
|
About MGC Pharma
MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based bio-pharma company developing and supplying affordable standardised phytomedicines to patients globally. The Company's founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality phytocannabinoid derived medicines for the growing demand in the medical markets in Europe, North America and Australasia. MGC Pharma has a robust product offering targeting two widespread medical conditions - epilepsy and dementia - and has further products in the development pipeline.
Employing its 'Nature to Medicine' strategy, MGC Pharma has partnered with renowned institutions and academia to optimise cultivation and the development of targeted phytocannabinoid derived medicines products prior to production in the Company's EU-GMP Certified manufacturing facility.
MGC Pharma has a number of research collaborations with world renowned academic institutions, and including recent research highlighting the positive impact of using specific phytocannabinoid formulations developed by MGC Pharma in the treatment of glioblastoma, the most aggressive and so far therapeutically resistant primary brain tumour.
MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.
Follow us through our social media channels:
Twitter: @MGC_Pharma
Facebook: @mgcpharmaceuticals
LinkedIn: MGC Pharmaceuticals Ltd.
Instagram: @mgc_pharma
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
